

REFERENCES

- 1) Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med* 355:2408-17, 2006.
- 2) Kantarjian H, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance: implications for future treatment strategies. *Ann Int Med* 145:913-923, 2006.
- 3) Hochhaus A, Kantarjian H, Baccarani M, Lipton J, Apperley J, Druker B, Facon T, Goldberg S, Cervantes F, Niederwieser D, Silver R, Stone R, Hughes T, Muller M, Ezzeddine R, Countouriotis A, Shah N. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. *Blood* 109:2303-2309, 2007.
- 4) Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. *N Eng J Med* 354(24):2542-2551, 2006.
- 5) Kantarjian H, Giles F, Quintás-Cardama A, Cortes J. Important therapeutic targets in CML. *Clin Cancer Res* 13(4):1089-97, 2007.